masoprocol has been researched along with Local Neoplasm Recurrence in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Desideri, S; Grossman, SA; Mikkelsen, T; Peereboom, D; Rosenfeld, MR; Supko, JG; Ye, X | 1 |
| Claros, C; Goldfine, ID; Harzstark, AH; Kerner, JF; Lin, A; Rosenberg, J; Ryan, CJ; Small, EJ; Youngren, JF | 1 |
1 trial(s) available for masoprocol and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Phase I study of terameprocol in patients with recurrent high-grade glioma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Female; Glioma; Humans; Male; Masoprocol; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome | 2012 |
1 other study(ies) available for masoprocol and Local Neoplasm Recurrence
| Article | Year |
|---|---|
A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Humans; Male; Masoprocol; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Receptor, IGF Type 1; Treatment Outcome | 2008 |